References
- Sherman SI. Thyroid carcinoma. Lancet361(9356), 501–511 (2003).
- Iervasi A, Iervasi G, Bottoni A et al. Diagnostic performance of a new highly sensitive thyroglobulin immunoassay. J. Endocrinol.82(2), 287–294 (2004).
- Machens A, Ukkat J, Brauckhoff M, Gimm O, Dralle H. Advances in the management of hereditary medullary thyroid cancer. J. Int. Med.257(1), 50–59 (2005).
- Jhiang SM. The RET proto-oncogene in human cancers. Oncogene19(49), 5590–5597 (2000).
- Santoro M, Melillo RM, Carlomagno F, Vecchio G, Fusco A. Minireview: RET: normal and abnormal functions. Endocrinology145(12), 5448–5451 (2004).
- Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res.63(7), 1454–1457 (2003).
- Carta C, Moretti S, Passeri L et al. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF). Clin. Endocrinol. (Oxford)64(1), 105–109 (2006).
- Nikiforova MN, Kimura ET, Gandhi M et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab.88(11), 5399–5404 (2003).
- Ciampi R, Knauf JA, Kerler R et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J. Clin. Invest.115(1), 94–101 (2005).
- Xing M. BRAF mutation in thyroid cancer. Endocrinol. Relat. Cancer12(2), 245–262 (2005).
- Alsanea O. Familial non medullary thyroid cancer. Curr. Treat. Options Oncol.1(4), 345–351 (2000).
- Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin. Endocrinol. (Oxford)61(3), 299–310 (2004).
- Gimm O. Thyroid cancer. Cancer Lett.163(2), 143–156 (2001).
- Zhang R, Straus FH, DeGroot LJ. Adenoviral-mediated gene therapy for thyroid carcinoma using thymidine kinase controlled by thyroglobulin promoter demonstrates high specificity and low toxicity. Thyroid11(2), 115–123 (2001).
- Takeda T, Inaba H, Yamazaki M et al. Tumor-specific gene therapy for undifferentiated thyroid carcinoma utilizing the telomerase reverse transcriptase promoter. J. Clin. Endocrinol. Metab.88(8), 3531–3538 (2003).
- Kitazono M, Chuman Y, Aikou T, Fojo T. Adenovirus HSV-TK construct with thyroid-specific promoter: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the camp pathway. Int. J. Cancer99(3), 453–459 (2002).
- Minemura K, Takeda T, Minemura K et al. Cell-specific induction of sensitivity to ganciclovir in medullary thyroid carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Endocrinology141(5), 1814–1822 (2000).
- Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature392(6673), 245–252 (1998).
- Schott M, Seissler J. Dendritic cell vaccination: new hope for the treatment of metastasized endocrine malignancies. Trends Endocrinol. Metab.14(4), 156–162 (2003).
- Vile RG, Russell SJ. Retroviruses as vectors. Br. Med. Bull.1(1), 12–30 (1995).
- Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science302(5644), 415–419 (2003).
- Barzon L, Stefani AL, Pacenti M, Palu G. Versatility of gene therapy vectors through viruses. Expert Opin. Biol. Ther.5(5), 639–662 (2005).
- Yi Y, Hahm SH, Lee KH. Retroviral gene therapy: safety issues and possible solutions. Curr. Gene Ther.5(1), 25–35 (2005).
- Ritter T, Lehmann M, Volk HD. Improvements in gene therapy: averting the immune response to adenoviral vectors. Biol. Drugs16(1), 3–10 (2002).
- Barzon L, Boscaro M, Palu G. Endocrine aspects of cancer gene therapy. Endocrinol. Rev.25(1), 1–44 (2004).
- Braiden V, Nagayama Y, Iitaka M, Namba H, Niwa M, Yamashita S. Retrovirus-mediated suicide gene/prodrug therapy targeting thyroid carcinoma using a thyroid-specific promoter. Endocrinology139(9), 3996–3999 (1998).
- Zhang R, Straus FH, DeGroot LJ. Cell-specific viral gene therapy of a Hurthle cell tumor. J. Clin. Endocrinol. Metab.87(3), 1407–1414 (2002).
- Kitazono M, Chuman Y, Aikou T, Fojo T. Construction of gene therapy vectors targeting thyroid cells: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3´,5´-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells. J. Clin. Endocrinol. Metab.86(2), 834–840 (2001).
- Takeda T, Yamazaki M, Minemura K et al. A tandemly repeated thyroglobulin core promoter has potential to enhance efficacy for tissue-specific gene therapy for thyroid carcinomas. Cancer Gene Ther.9(10), 864–874 (2002).
- Barzon L, Barzon L, Bonaguro R et al. Transcriptionally targeted retroviral vector for combined suicide and immunomodulating gene therapy of thyroid cancer. J. Clin. Endocrinol. Metab.87(11), 5304–5311 (2002).
- Nagayama Y, Nishihara E, Iitaka M, Namba H, Yamashita S, Niwa M. Enhanced efficacy of transcriptionally targeted suicide gene/prodrug therapy for thyroid carcinoma with the Cre-loxP system. Cancer Res.59(13), 3049–3052 (1999).
- Mian C, Lacroix L, Alzieu L et al. Sodium iodide symporter and pendrin expression in human thyroid tissues. Thyroid11(9), 825–830 (2001).
- Cho JY. A transporter gene (sodium iodide symporter) for dual purposes in gene therapy: imaging and therapy. Curr. Gene Ther.2(4), 393–402 (2002).
- Boland A, Ricard M, Opolon P et al. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res.60(13), 3484–3492 (2000).
- Mandell RB, Mandell LZ, Link CJ Jr. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res.59(3), 661–668 (1999).
- Spitzweg C, Morris JC. The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin. Endocrinol. (Oxford)57(5), 559–574 (2002).
- Smit JW, Shroder-van der Elst JP, Karperien M et al. Re-establishment of in vitro and in vivoiodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line. Thyroid10(11), 939–943 (2000).
- Huang M, Batra RK, Kogai T et al. Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther.8(8), 612–618 (2001).
- Boland A, Magnon C, Filetti S et al. Transposition of the thyroid iodide uptake and organification system in non thyroid tumor cells by adenoviral vector-mediated gene transfers. Thyroid12(1), 19–26 (2002).
- Wenzel A, Upadhyay G, Schmitt TL, Loos U. Iodination of proteins in TPO transfected thyroid cancer cells is independent of NIS. Mol. Cell Endocrinol.213(1), 99–108 (2003).
- Greten TF, Jaffee EM. Cancer vaccines. J. Clin. Oncol.17(3), 1047–1060 (1999).
- Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA90(8), 3539–3543 (1993).
- Lamont AG, Adorini L. IL-12: a key cytokine in immune regulation. Immunol. Today17(5), 214–217 (1996).
- Melero I, Mazzolini G, Narvaiza I, Qian C, Chen L, Prieto J. IL-12 gene therapy for cancer: in synergy with other immunotherapies. Trends Immunol.22(3), 113–115 (2001).
- Zhang R, Baunoch D, DeGroot LJ. Genetic immunotherapy for medullary thyroid carcinoma: destruction of tumors in mice by in vivo delivery of adenoviral vector transducing the murine interleukin-2 gene. Thyroid8(12), 1137–1146 (1998).
- Zhang R, DeGroot LJ. Genetic immunotherapy of established tumours with adenoviral vectors transducing murine interleukin-12 (mIL12) subunits in a rat medullary thyroid carcinoma model. Clin. Endocrinol. (Oxford)52(6), 687–694 (2000).
- Barzon L, Pacenti M, Taccaliti A et al. A pilot study of combined suicide/cytokine gene therapy in two patients with end-stage anaplastic thyroid carcinoma. J. Clin. Endocrinol. Metab.90(5), 2831–2834 (2005).
- Maxon HR III, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol. Metab. Clin. North Am.19(3), 685–718 (1990).
- Drosten M, Frilling A, Stiewe T, Putzer BM. A new therapeutic approach in medullary thyroid cancer treatment: inhibition of oncogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant. Surgery132(6), 991–997 (2002).
- Drosten M, Stiewe T, Putzer BM. Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model. Hum. Gene Ther.14(10), 971–982 (2003).
- Zhang R, DeGroot LJ. Gene therapy of established medullary thyroid carcinoma with herpes simplex viral thymidine kinase in a rat tumor model: relationship of bystander effect and antitumor efficacy. Thyroid10(4), 313–319 (2000).
- Drosten M, Putzer BM. Gene therapeutic approaches for medullary thyroid carcinoma treatment. J. Mol. Med.81(7), 411–419 (2003).
- Jiang S, Altmann A, Grimm D et al. Tissue-specific gene expression in medullary thyroid carcinoma cells employing calcitonin regulatory elements and AAV vectors. Cancer Gene Ther.8(7), 469–472 (2001).
- Yamazaki M, Zhang R, Straus FH et al. Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12. Gene Ther.9(1), 64–74 (2002).
- Bockmann M, Drosten M, Putzer BM. Discovery of targeting peptides for selective therapy of medullary thyroid carcinoma. J. Gene Med.7(2), 179–188 (2005).
- Haupt K, Siegel F, Lu M et al. Induction of a cellular and humoral immune response against preprocalcitonin by genetic I: a potential new treatment for medullary thyroid carcinoma. Endocrinology142(3), 1017–1023 (2001).
- Chiocca EA. Oncolytic viruses. Nature Rev. Cancer2(12), 938–950 (2002).
- Schott M, Scherbaum WA. Immunotherapy and gene therapy of thyroid cancer. Minerva Endocrinol.29(4), 175–187 (2004).
- Wickham TJ. Ligand-directed targeting of genes to the site of disease. Nature Med.9(1), 135–139 (2003).
- Fagin JA. Tumor suppressor genes in human thyroid neoplasms: p53 mutations are associated undifferentiated thyroid cancers. J. Endocrinol. Invest.18(2), 140–142 (1995).
- Fagin JA, Tang SH, Zeki K, Di Lauro R, Fusco A, Gonsky R. Re-expression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53. Cancer Res.56(4), 765–771 (1996).
- Fang B, Roth JA. Tumor-suppressing gene therapy. Cancer Biol. Ther.2(4 Suppl. 1), S115–S121 (2003).
- Kim SB, Ahn IM, Park HJ et al. Growth inhibition and chemosensitivity of poorly differentiated human thyroid cancer cell line (NPA) transfected with p53 gene. Head Neck23(3), 223–229 (2001).
- Xing M, Usadel H, Cohen Y et al. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res.63(9), 2316–2321 (2003).
- Kang HC, Ohmori M, Harii N, Endo T, Onaya T. Pax-8 is essential for regulation of the thyroglobulin gene by transforming growth factor-β1. Endocrinology142(1), 267–275 (2001).
- Shimura H, Suzuki H, Miyazaki A et al. Transcriptional activation of the thyroglobulin promoter directing suicide gene expression by thyroid transcription factor-1 in thyroid cancer cells. Cancer Res.61(9), 3640–3646 (2001).
- Kim NW, Piatyszek MA, Prowse KR et al. Specific association of human telomerase activity with immortal cells and cancer. Science266(5193), 2011–2015 (1994).
- Giet R, Petretti C, Prigent C. Aurora kinases, aneuploidy and cancer, a coincidence or a real link? Trends Cell Biol.15(5), 241–250 (2005).
- Ota T, Suto S, Katayama H et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res.62(18), 5168–5177 (2002).
- Sorrentino R, Libertini S, Pallante PL et al. Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J. Clin. Endocrinol. Metab.90(2), 928–935 (2005).
- Pallante P, Berlingieri MT, Troncone G et al. UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas. Br. J. Cancer93(4), 464–471 (2005).
- Hershko A, Ciechanover A. The ubiquitin system. Ann. Rev. Biochem.67, 425–479 (1998).
- Joazeiro CA, Weissman AM. RING finger proteins: mediators of ubiquitin ligase activity. Cell102(5), 549–552 (2000).
- Bischoff JR, Kirn DH, Williams A et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science274(5286), 373–376 (1996).
- Vollmer CM, Ribas A, Butterfield LH et al. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Res.59(17), 4369–4374 (1999).
- Portella G, Pacelli R, Libertini S et al. ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells. J. Clin. Endocrinol. Metab.88(10), 5027–5032 (2003).
- Marsee DK, Vadysirisack DD, Morrison CD et al. Variable expression of coxsackie-adenovirus receptor in thyroid tumors: implications for adenoviral gene therapy. Thyroid15(9), 977–987 (2005).
- Kesmodel S, Prabakaran I, Canter R, Menon C, Molnar-Kimber K, Fraker D. Virus-mediated oncolysis of thyroid cancer by a replication-selective adenovirus driven by a thyroglobulin promoter-enhancer region. J. Clin. Endocrinol. Metab.90(6), 3440–3448 (2005).
- Berlingieri MT, Santoro M, Battaglia C, Grieco M, Fusco A. The adenovirus E1A gene blocks the differentiation of a thyroid epithelial cell line, however the neoplastic phenotype is achieved only after cooperation with other oncogenes. Oncogene8(2), 249–255 (1993).
- Sauthoff H, Pipiya T, Heitner S et al. Impact of E1a modifications on tumor-selective adenoviral replication and toxicity. Mol. Ther.10(4), 749–757 (2004).
- Schott M, Seissler J, Lettmann M, Fouxon V, Scherbaum WA, Feldkamp J. Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J. Clin. Endocrinol. Metab.86(10), 4965–4969 (2001).
- Stift A, Sachet M, Yagubian R et al. Dendritic cell vaccination in medullary thyroid carcinoma. Clin. Cancer Res.10(9), 2944–2953 (2004).
- Nemunaitis J, Cunningham C, Buchanan A et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther.8(10), 746–759 (2001).
- Nagayama Y, Shigematsu K, Namba H, Zeki K, Yamashita S, Niwa M. Inhibition of angiogenesis and tumorigenesis, and induction of dormancy by p53 in a p53-null thyroid carcinoma cell line in vivo. Anticancer Res.20(4), 2723–2728 (2000).
- Nagayama Y, Yokoi H, Takeda K et al. Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J. Clin. Endocrinol. Metab.85(11), 4081–4086 (2000).
- Chung HK, Yi YW, Jung NC et al. Gadd45γ expression is reduced in anaplastic thyroid cancer and its re-expression results in apoptosis. J. Clin. Endocrinol. Metab.88(8), 3913–3920 (2003).
- Weng LP, Gimm O, Kum JB et al. Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death. Hum. Mol. Genet.10(3), 251–258 (2001).
- Iuliano R, Trapasso F, Le Pera I et al. An adenovirus carrying the rat protein tyrosine phosphatase suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo. Cancer Res.63(4), 882–886 (2003).
- Cerutti J, Trapasso F, Battaglia C et al. Block of c-myc expression by antisense oligonucleotides inhibits proliferation of human thyroid carcinoma cell lines. Clin. Cancer Res.2(1), 119–126 (1996).
- Berlingieri MT, Manfioletti G, Santoro M et al. Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol. Cell Biol.15(3), 1545–1553 (1995).
- Scala S, Portella G, Fedele M, Chiappetta G, Fusco A. Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc. Natl Acad. Sci. USA97(8), 4256–4261 (2000).
- Martelli ML, Iuliano R, Le Pera I et al. Inhibitory effects of peroxisome poliferator-activated receptor γ on thyroid carcinoma cell growth. J. Clin. Endocrinol. Metab.87(10), 4728–4735 (2002).
- Braiden V, Nagayama Y, Iitaka M, Namba H, Niwa M, Yamashita S. Retrovirus-mediated suicide gene/prodrug therapy targeting thyroid carcinoma using a thyroid-specific promoter. Endocrinology139(9), 3996–3999 (1998).
- Nishihara E, Nagayama Y, Mawatari F et al. Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo. Endocrinology138(11), 4577–4583 (1997).